CMV-associated Immunomodulation in Renal Transplant Patients
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Assistance Publique - Hôpitaux de Paris
- Trial code
- NCT06976008
- Record updated
- 12 September 2025
- Original description
Cytomegalovirus (CMV) infection has been associated with an increased risk of bacterial, fungal and viral infections in solid organ transplant recipients. The purpose of this study to evaluate if the occurrence of CMV viremia modify the ability to develop optimal immune responses against other pathogens in kidney transplant recipients (heterologous immunity). The objective of this project is to identify the immune pathways affected by CMV in the context of immunosuppression associated with kidney transplantation.Read full original descriptionShow less
Cytomegalovirus (CMV) infection has been associated with an increased risk of bacterial, fungal and viral infections in solid organ transplant recipients. The purpose of this study to evaluate if the occurrence of CMV viremia modify the ability to develop optimal immune responses against other pathogens in kidney transplant recipients (heterologous immunity). The objective of this project is to identify the immune pathways affected by CMV in the context of immunosuppression associated with kidney transplantation.
Inclusion: st cohort :; Age > 18 years; patients with end-stage renal failure programmed for kidney transplantation with a live donor; nd cohort :; Age > 18 years; kidney transplant recipient with CMV viremia.
Exclusion: patients receiving a desensitization protocol (ABO or anti-HLA); Patients under guardianship, curatorship, legal protection; For patients with end-stage renal failure scheduled to receive a kidney transplant from a living donor :; Patients with an active viral (other than CMV), bacterial or fungal infection at the time of inclusion.